1. Products
  2. Solutions
  3. Insights+
  4. News & content
  5. About
-
  1. Products
  2. Solutions
  3. Insights+
  4. News & content
  5. About
  1. Launch

Cellshoot Therapeutics, Inc.

Have updates for this profile?  Please contribute data

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.

Year established

2021

Location

Tokyo Japan

Primary Industry

Biotechnology

About

Based in Tokyo, Japan, and founded in 2021 by CEO Jie Zhang, Ph.D., and co-founder Liangfang Zhang, Ph.D., Cellshoot Therapeutics, Inc. operates as a pharmaceutical research company, providing drug discovery target molecules and creating drug candidates by utilising the technology of intracellular protein pathway analysis. In August 2022, Cellshoot Therapeutics, Inc. raised JPY 230 million in seed funding from Kyoto University Innovation Capital, SMBC Venture Capital, and Fast Track Initiative. Cellshoot Therapeutics provides protein localization and the modification-based covariation network analysis method (PLOM-CON) for extracting and analysing the quantity and quality of proteins from fluorescent antibody-producing cells. The company provides a semi-intact cell sealing method in which molecules are introduced from outside the cells and then into the cells. As of 2023, the company serves industries such as pharmaceuticals, medicine development, and research and development.
Current Investors
SMBC Venture Capital, Fast Track Initiative, Kyoto University Innovation Capital

Request a demo to show more

Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.cellshoot.co.jp
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.